Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 90
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more

Conditions: Obesity, Weight Loss
Interventions: Rimonabant (SR141716); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,045 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 42 more

Conditions: Major Depressive Disorder
Interventions: Quetiapine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 66 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • San Diego, California • Fort Myers, Florida + 10 more

Conditions: Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions: Valproate, Placebo, Patch; Drug · Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neuroendocrine Tumors in Lung
Interventions: Lanreotide (Autogel formulation), Placebo, Best Supportive Care; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Giant Cell Arteritis
Interventions: Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more

Conditions: Anemia, Kidney Disease
Interventions: AKB-6548, Placebo; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Pine Bluff, Arkansas • Covina, California • Los Angeles, California + 25 more

Conditions: Parkinson's Disease
Interventions: Istradefylline (KW-6002); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Princeton, New Jersey

Conditions: Schizophrenia
Interventions: bitopertin [RO4917838], olanzapine, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more

Conditions: Chronic Rhinitis
Interventions: NEUROMARK™ System, Sham Device; Device
Lead sponsor: Neurent Medical; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Roseville, California • Colorado Springs, Colorado + 5 more

Conditions: COVID-19
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more

Conditions: Knee Osteoarthritis
Interventions: balicatib (AAE581); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 223 participants
Timeline: Started 2004
U.S. locations: 1
States / cities: Anniston, Alabama

Conditions: Psoriasis
Interventions: ustekinumab, placebo; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more

Conditions: Myasthenia Gravis, Generalized
Interventions: mycophenolate mofetil (CellCept), placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 10
States / cities: Sun City, Arizona • Sacramento, California • Miami, Florida + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-04603629, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more

Conditions: Atopic Dermatitis
Interventions: YR001 ointment, Placebo; Drug · Other
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more

Conditions: Diabetic Foot Ulcer
Interventions: Esmolol hydrochloride, Placebo gel; Drug
Lead sponsor: Novalead Pharma Private Limited; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Crohn's Disease
Interventions: Brodalumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 18
States / cities: Birmingham, Alabama • Dothan, Alabama • Lowell, Arkansas + 15 more

Conditions: Pruritus
Interventions: Dupilumab, Placebo, Fexofenadine (loratadine if not available); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Bakersfield, California • La Jolla, California • Washington D.C., District of Columbia + 16 more

Conditions: Chronic Kidney Diseases
Interventions: Placebo, KBP-5074; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 65
States / cities: Foley, Alabama • Huntsville, Alabama • Mesa, Arizona + 47 more

Conditions: Pancreatic Cancer
Interventions: ABTL0812, Folfirinox, Placebo; Drug
Lead sponsor: Ability Pharmaceuticals SL; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more

Conditions: Locally Advanced Rectal Cancer
Interventions: Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg, Peposertib 250 mg, Capecitabine, Radiotherapy (RT); Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Aurora, Colorado • New Haven, Connecticut • Great Neck, New York + 7 more

Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions: The Lilac Device, Sham device; Device
Lead sponsor: Luminate Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 17
States / cities: Poway, California • Norwich, Connecticut • Hialeah, Florida + 13 more

Conditions: Rheumatoid Arthritis
Interventions: AIN457, Placebo, Abatacept; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more

Search by objective public record fields.

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

Obese Patients With or Without Comorbidities (RIO-North America)

Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder

Valproate for the Treatment of Residual Amblyopia

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis

A Study of Baricitinib (LY3009104) in Participants With COVID-19

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)